RJA
EIGR

Raymond James & Associates’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Raymond James & Associates’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-77
Closed -$657K – 2457
2015
Q1 		$657K Buy
77
+37
+93% +$323K ﹤0.01% 1901
2014
Q4 		$355K Buy
+40
New +$232K ﹤0.01% 2067

Other funds holding EIGR

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Raymond James & Associates's EIGR Position: Q2 2015 in Review

Raymond James & Associates sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2015, closing a stake of 77 shares — an estimated $657K sold.

Raymond James & Associates first reported a position in EIGR in Q4 2014 and held it in 2 quarters. The position peaked at $657K in Q1 2015. 44 funds tracked by Wall St. Rank hold EIGR as of Q2 2015.

  • Raymond James & Associates reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • Raymond James & Associates sold 77 Eiger BioPharmaceuticals, Inc. shares in Q2 2015, an estimated $657K.
  • Raymond James & Associates first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2014 and held it in 2 quarters.
  • Raymond James & Associates's Eiger BioPharmaceuticals, Inc. position peaked at $657K in Q1 2015.
  • 44 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2015.

Based on Raymond James & Associates's 13F filing for Q2 2015, filed 13 Aug 2015.